tbuckley/cabot-search huggingface dataset:
AB0594 Anti-RNA Pol III Antibodies in Systemic Sclerosis - The Prevalence and Usefulness
Authors: E. Wielosz, M. Dryglewska, M. Majdan
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Anti-RNA Polimerase III (a-RNA Pol III) antibodies are markers antibodies which are detected in sera of patients with systemic sclerosis (SSc). They are found in approximately 20% of SSc, particularly with diffuse subtype. According to literature a-RNA Pol III antibodies are strongly associated with scleroderma renal crisis (SRC). They are also correlated with higher rate of SSc-related mortality. Additionally, there are many data which reported that, a-RNA Pol III antibodies are associated with an increased risk of malignancy in patients with SSc. <h3>Objectives</h3> The aim of the study was assess the prevalence of a-RNA Pol III antibodies in patients with systemic sclerosis and to identify differences in the picture of the disease in patients with the presence of a-RNA Pol III. <h3>Methods</h3> The study was performed in 126 (98-female and 28-male) consecutive SSc patients treated in Department of Rheumatology. Patients fulfilled the ACR classification criteria of SSc (60 have diffuse SSc-dcSSc and 66 limited SSc – lcSSc). The subtype of SSc, incidence of internal organ involvement, the prevalence of malignancy, death and serological profile were determined in the whole data group. The study group were studied according to the presence of antibodies applying commercial test – EUROLINE Systemic Sclerosis Profile. Detection and interpretation of results was carried out electronically using the specific program Euroimmun– EUROLINEScan. Due to the presence of a-RNA Pol III antibodies, patients were divided into two groups a-RNA Pol III(+) SSc – 19 pts and a-RNA Pol III(−) SSc – 107 pts. <h3>Results</h3> According to our data a- RNA Pol III antibodies were present in 19/126 patients with SSc (15%), including the a-RNA Pol III 11 were present in 16 and a-RNA Pol III 155 in 14. In this group of 13 (68,4%) pts had no other marker to SSc antibodies as a anticentromere, anti-topoisomerase I. Moreover, in our study group, a-RNA Pol III antibodies were more common in patients with dcSSc (p=0,049), compare to lcSSc. We also showed a significant positive association with a-RNA Pol III antibodies and occurrence of malignancy (p=0,007), SRC (p=0,001) and decreased DLCO (p=0,007). There was no relationship between the presence of a-RNA Pol III and other organ involvement, digital ulcerations or calcinosis. <h3>Conclusions</h3> 1. Anti- a-RNA Pol III antibodies are quite common in patients with systemic sclerosis, particularly with diffuse subtype. 2. In more than 50% of patients a-RNA Pol III antibodies may be present as the sole marker to SSc antibodies. 3. In SSc a-RNA Pol III antibodies are frequently associated with malignancy occurrence, kidney and lung involvement. <h3>Disclosure of Interest</h3> None declared
Micafungin Does Not Influence the Concentration of Tacrolimus in Patients after Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Noriyasu Fukuoka, Osamu Imataki, Hiroaki Ohnishi, Akira Kitanaka, Yoshitsugu Kubota, Terukazu Tanaka, Toshihiko Ishida
Journal: Blood (2007)
Carfilzomib Combined with Thalidomide and Dexamethasone (CARTHADEX) As Induction Treatment Prior to High-Dose Melphalan (HDM) in Newly Diagnosed Patients with Multiple Myeloma (MM). A Trial of the European Myeloma Network EMN
Authors: Pieter Sonneveld, Emilie Hacker, Sonja Zweegman, Marie Jose Kersten, Edo Vellenga, Marinus van Marwijk-Kooy, Okke de Weerdt, Sarah Lonergan, Antonio Palumbo, Henk M. Lokhorst
Journal: Blood (2011)
Two vs Three Doses of Human Papillomavirus Vaccine
Authors: Lauri E. Markowitz, Elissa Meites, Elizabeth R. Unger
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Genome-Wide Copy Number Analyses Correlated with Outcomes in Untreated Multiple Myeloma Patients
Authors: Vishwanathan Hucthagowder, Mark Fiala, Doug Cox, Keith E. Stockerl-Goldstein, Michael H. Tomasson, John F. DiPersio, Ravi Vij, Shashikant Kulkarni
Journal: Blood (2012)
OP0038 Improved Survival in Dermatomyositis and Polymyositis: A General Population-Base Study: Table 1.
Authors: L. Li, L.M. Belvedere, E.C. Sayre, J.A. Avina-Zubieta
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Dermatomyositis (DM) and polymyositis (PM) are associated with significant mortality and morbidity. However, mortality trends for these two diseases are unknown, especially in the general population context. <h3>Objectives</h3> To address this knowledge gap, we assess mortality trends for individuals with PM and DM between January 1, 1997 and December 31, 2012 in the general population. <h3>Methods</h3> Using an administrative health database from province of British Columbia, Canada, we identified all incident cases of both PM and DM and up to 10 non-disease controls matched on sex-, age- and entry-time for each. Study cohorts for both PM and DM were divided into two subgroups based on the year of diagnosis (ie., 1997–2004 and 2005–2012).Mortality rates were calculated, as well as hazard ratios (HR) using a Cox proportional hazard model. HRs were adjusted for potential confounders (e.g., number of hospitalization and outpatient visits, Charlson9s comorbidity index, glucocorticoid use, cardiovascular drugs, cox-2 inhibitors). <h3>Results</h3> Mortality rates (cases per 1000 person-years) in the early cohorts (ie.,1997–2004) for PM and DM patients were considerably higher than those in the later cohorts (ie., 2005–2012) (for PM: 226.1 vs 73.3; for DM: 287.0 vs 56.9). In contrast, smaller improvements were observed in the comparison groups (for PM: 28.9 vs 16.2; for DM: 31.0 vs 13.5). Corresponding to these two time periods, HRs for mortality for PM were 5.6 (95% CI, 3.2–9.9) and 3.1 (95%CI, 1.8–5.3), respectively, and 8.0 (95% CI, 4.0–16.0) and 2.9 (95%CI, 1.7–5.2) for DM, respectively. Testing for difference between incident cohorts via an interaction term were all significant (see table). <h3>Conclusions</h3> This population-based study shows that the survival of PM and DM patients has improved in recent years, suggesting that new treatment strategies and improved management of PM and DM and its associated complications have led to significant improvements in PM- and DM-associated mortality. <h3>Disclosure of Interest</h3> None declared
Salvage Therapy with Lenalidomide and Dexamethasone (LDex) In Patients with Advanced AL Amyloidosis Refractory to Both Melphalan and Bortezomib
Authors: Giovanni Palladini, Paola Russo, Paolo Milani, Andrea Foli, Letizia Zenone Bragotti, Laura Obici, Francesca Lavatelli, Silvia Brugnatelli, Vittorio Perfetti, Rosangela Invernizzi, Giampaolo Merlini
Journal: Blood (2010)
Multi-Dimensional Flow Cytometric Analysis of Acute Myelomonocytic Leukemia: Evaluation of Disease Complexity and Effects on Host Hematopoiesis.
Authors: Ben-Zion Katz, Zvi Kam, Varda Deutsch, Shoshana Bar-On, Ofira Ben-Tal, Nir Cohen, Elizabeth Naparstek, Benjamin Geiger, Eli Zamir
Journal: Blood (2004)
Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland
Authors: Su Wai Maung, Cian McEllistrim, Amjad Hayat, Margaret Murray, Michael O'Dwyer, Patrick Thornton, Emma Groarke, Denis O'Keeffe, Maeve Leahy, Aine Burke, Peter O'Gorman, Carmel Weldon, Gerard Crotty, Meegahage Ratnakanthi Perera, Cathie Burke, Johnny McHugh, Helen Enright, Ronan Desmond
Journal: Blood (2015)
In Vivo Biosafety Model To Assess Risk of Adverse Events from Retroviral and Lentiviral Vectors.
Authors: Gerhard Bauer, Mo Dao, Scott Case, Todd Meyerrose, Louisa Wirthlin, Phillip Herrbrich, Ping Zhou, Xiuli Wang, Susie Csik, Jesusa Arevalo, Dianne Skelton, Jon Walker, Karen Pepper, Gay Crooks, Donald Kohn, Jan Nolta
Journal: Blood (2007)
Research needs in breast cancer
Authors: F. Cardoso, N. Harbeck, C.H. Barrios, J. Bergh, J. Cortés, N. El Saghir, P.A. Francis, C.A. Hudis, S. Ohno, A.H. Partridge, G.W. Sledge, I.E. Smith, K.A. Gelmon
Journal: Annals of Oncology (2016)

New research questions emerge as medical needs continue to evolve and as we improve our understanding of cancer biology and treatment of malignancies. Although significant advances have been made in some areas of breast cancer research resulting in improvements in therapies and outcomes over the last few decades, other areas have not benefited to the same degree and we continue to have many gaps in our knowledge. This article summarizes the 12 short and medium-term clinical research needs in breast cancer deemed as priorities in 2016 by a panel of experts, in an attempt to focus and accelerate future research in the most needed areas: (i) de-escalate breast cancer therapies in early breast cancer without sacrificing outcomes; (ii) explore optimal adjuvant treatment durations; (iii) develop better tools and strategies to identify patients with genetic predisposition; (iv) improve care in young patients with breast cancer; (v) develop tools to speed up drug development in biomarker-defined populations; (vi) identify and validate targets that mediate resistance to chemotherapy, endocrine therapy and anti-HER2 therapies; (vii) evaluate the efficacy of local-regional treatments for metastatic disease; (viii) better define the optimal sequence of treatments in the metastatic setting; (ix) evaluate the clinical impact of intra-patient heterogeneity (intra-tumor, inter-tumor and inter-lesion heterogeneity); (x) better understand the biology and identify new targets in triple-negative breast cancer; (xi) better understand immune surveillance in breast cancer and further develop immunotherapies; and (xii) increase survivorship research efforts including supportive care and quality of life.
Prevalence of serrated polyposis syndrome in an FIT-based colorectal cancer screening cohort in Italy
Authors: Dora Colussi, Rocco Maurizio Zagari, Beatrice Morini, Margherita Fabbri, Amedeo Montale, Cesare Hassan, Carlo Senore, Franco Bazzoli, Luigi Ricciardiello
Journal: Gut (2016)

To the Editor 

We read with interest the recent data reported by IJspeert et al ,1 Biswas et al 2 and Moreira et al 3 whom evaluated the prevalence of serrated polyposis syndrome (SPS), a disease characterised by the development of multiple serrated polyps throughout the colon with an increased risk to develop colorectal cancer (CRC),4 inside CRC screening programmes. A guaiac faecal occult blood test cohort from the UK showed a frequency of SPS ranging from 0.03% to 0.66%.1 ,2 Other cohorts based on primary colonoscopy showed a prevalence of SPS between 0.1% and 0.4%.1 The only published data on SPS frequency within faecal immunochemical test (FIT) programmes are from Spain and ranged from 0.34% to 0.8%.1 ,3 Since FIT has widely become the method of choice for …
The GSK3β-Phosphorylation Sites in the DEK-Portion Are Indispensable for the Leukemogenic Potential of the DEK/CAN Fusion Protein in t(6;9)-Positive Acute Myeloid Leukemia
Authors: Claudia Oancea, Maria Heinßmann, Nathalie Guillen, Oliver G. Ottmann, Martin Ruthardt
Journal: Blood (2014)
Reply to Herney Andrés García-Perdomo and Ramiro Manzano Nunez's Letter to the Editor Re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer M. Sinnott, Rachel S. Kelly, Lorelei A. Mucci, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol 2016;70:974–82
Authors: Jennifer R. Rider, Kathryn M. Wilson, Jennifer A. Sinnott, Rachel S. Kelly, Lorelei A. Mucci, Edward L. Giovannucci
Journal: European Urology (2016)
Unrelated Hematopoietic Blood Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML) in First Remission.
Authors: Gerhard Ehninger, Walter E. Aulitzky, Heinrich Bodenstein, Martin Bornhaeuser, Hermann Einsele, Christoph Faul, Jurgen Finke, Arnold Ganser, Martin Gramatzki, Mathias Haenel, Gisela Helm, Anthony D. Ho, Andreas Jakob, Owe Knigge, Hartmut Link, Rolf Mahlberg, Ulrich Mahlknecht, Andreas Neubauer, Norbert Schmitz, Markus A. Schaich, Kerstin Schaefer-Eckart, Silke Soucek, Thomas Wagner, Hannes Wandt, Axel R. Zander
Journal: Blood (2006)
Leukemia Microenvironment-Specific Galectin-3 Expression of Leukemic Cells Promotes Malignant Niche Formation and Bone Marrow Lodgment of Leukemic Cells in Chronic Myelogenous Leukemia
Authors: Junya Kuroda, Mio Yamamoto, Eishi Ashihara, Hisao Nagoshi, Tsutomu Kobayashi, Yosuke Matsumoto, Nasa Sasaki, Yuji Shimura, Miki Kiyota, Ryuko Nakayama, Shigeo Horiike, Taira Maekawa, Masafumi Taniwaki
Journal: Blood (2011)
Conflicting Signals for Cancer Treatment
Authors: Pierre Sujobert, Alain Trautmann
Journal: Cancer Research (2016)

Next-generation sequencing technologies have provided us with a precise description of the mutational burden of cancers, making it possible to identify targetable oncogene addictions. However, the emergence of resistant clones is an inevitable limitation of therapies targeting these addictions. Alternative approaches to cancer treatment are therefore required. We propose here a novel approach, based on the notion of conflicting signals and on a phenotypic description of cancer cells. "Phenotype" is an inherently complex notion that we describe in the conceptual framework of the epigenetic landscape, with a view to bridging the gap between theory and practice at the patient's bedside. By passing from theory to the description of several examples, we will illustrate how this approach can facilitate data analysis and the design of new strategies for cancer treatment. Cancer Res; 76(23); 6768-73. ©2016 AACR.
A GITIL Prospective Randomized Multicenter Phase III Study of High Dose Sequential Chemotherapy with Rituximab (R-HDS) and Autologous Transplantation (ASCT) of Peripheral Blood Stem Cells Versus CHOP and Rituximab Delivered Every 14 Days (R-CHOP-14) in High-Risk Patients with Diffuse Large B-Cell Lymphomas (DLBCL): Interim Analysis on Feasibility and Toxicity (Protocol R-HDS 0305).
Authors: Sergio Cortelazzo, Atto Billio, Alessandro Rambaldi, Corrado Tarella, Ingnazio Majolino, Alessandro M. Gianni, Paolo Corradini, Catterina Patti, Salvo Mirto, Giovanna Borrelli, Roberto Marchioli9
Journal: Blood (2007)
Applicability of DHPLC for Low Sensitive Residual Disease Detection in RUNX1 and CEBPA Mutated AML.
Authors: Susanne Schnittger, Frank Dicker, Christiane Eder, Jana Sundermann, Alexandra Spiel, Nicole Wendland, Tamara Weiss, Claudia Haferlach, Wolfgang Kern, Torsten Haferlach
Journal: Blood (2009)
AB0238 The Performance of A Single Centre Interventional Clinic in Early Rheumatoid Arthritis: Table 1.
Authors: R. Ješe, A. Ambrožič, N. Gašperšič, A. Hočevar, B. Lestan, M. Plešivčnik Novljan, S. Praprotnik, Ž. Rotar, A. Šipek, D. Šuput Skvarča, M. Pavic Nikolic, M. Tomsic
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> In early rheumatoid arthritis (RA), first assessment by a rheumatologist and/or initiation of disease-modifying anti-rheumatic drugs (DMARD) within 12 weeks of symptom onset are associated with a significant benefit in long-term disease outcome.<sup>1,2</sup> <h3>Objectives</h3> To determine the proportion of patients with newly diagnosed RA in whom first rheumatology assessment and/or initiation of DMARD therapy was within the desired time frame. <h3>Methods</h3> A retrospective chart review of adult patients diagnosed with RA during year 2014 and the first half of year 2015 was performed at our rheumatology department, which is a part of an integrated secondary/tertiary teaching hospital that provides rheumatology services for a population of more than 500.000 residents. Potential cases were identified by searching the electronic medical records for ICD-10 codes M05.* and M06.* Electronic and paper records of patients were then thoroughly reviewed. Dates were recorded for onset of inflammatory joint symptoms, referral to rheumatologist, initial assessment by a rheumatologist and initiation of DMARD therapy. The percentage of patients assessed by a rheumatologist and/or treated with a DMARD within 12 weeks of symptom onset and the median times for delay were then calculated. <h3>Results</h3> Between 01.01.2014 and 30.06.2015, 188 new cases of RA were identified at our Department of Rheumatology. Of those, 153 (81.4%) were referred to our early interventional clinic. Within 12 weeks of symptom onset, 89 (47.3%) new RA patients were examined by a rheumatologist and 68 (36.2%) were started on DMARD therapy; the median time from symptom onset to consultation was 12.8 (IQR 4.9–27.7) weeks, median time from referral to consultation was 1 (IQR 1–3) day and median DMARD treatment delay was 16.1 (IQR 8.6–32.8) weeks. <h3>Conclusions</h3> 47% of new RA patients were assessed by a rheumatologist and 36% were treated with a DMARD within the recommended time frame of 12 weeks. Most of the treatment delay was due to the time elapsed between symptom onset and referral to a rheumatologist. These results substantiate the efficacy of our early interventional clinic in diagnosing and treating patients with early RA: despite the heavily protracted nationwide waiting times for first rheumatologist assessment and significantly (40%) lower number of rheumatologists per capita compared to European Union average, the percentage of timely treated patients was comparable to recent reports. <h3>References</h3> Van der Linden MPM, et al. Arthritis Rheum, 2010;62(12):3537–3546. Raza K, et al. Ann Rheum Dis, 2011;(70)10:1822–1825 [MT1]. <h3>Disclosure of Interest</h3> None declared
An Interim 4-Year Analysis of Prospective Multicenter Observational Study of PNH-Type Cells in Japanese Patients with Bone Marrow Failure Syndrome (OPTIMA study)
Authors: Yukari Shirasugi, Hideyoshi Noji, Tsutomu Shichishima, Chiharu Sugimori, Naoshi Obara, Shigeru Chiba, Haruhiko Ninomiya, Yoshihiko Nakamura, Kiyoshi Ando, Yuji Yonemura, Tatsuya Kawaguchi, Kohei Hosokawa, Yasutaka Ueda, Jun-Ichi Nishimura, Yuzuru Kanakura, Shinji Nakao
Journal: Blood (2015)
PWE-031a Exploring Fatigue in Inflammatory Bowel Disease – A Descriptive Phenomenological Study
Authors: WJ Czuber-Dochan, J Armes, E Ream, C Norton, M Artom
Journal: Gut (2016)

<h3>Introduction</h3> Fatigue is frequently reported by people with active (86%) and quiescent (41%) inflammatory bowel disease (IBD).<sup>1</sup> It is considered a complex and multifaceted symptom; it affects many aspects of individuals’ lives. To date, limited research has investigated IBD-fatigue;<sup>2</sup> little is known about specific areas of life affected by it or how people with IBD manage it. <h3>Methods</h3> Descriptive phenomenology with unstructured, in-depth interviews.<sup>3</sup> Twenty participants with IBD and reporting fatigue were purposively selected and interviewed face-to-face. Interviews were audio-recorded, transcribed verbatim and analysed using Moustakas’ method. Data were analysed at individual and composite (group) level, and provided a description (texture) and an explanation (structure) of the studied phenomenon. <h3>Results</h3> A wide range of terminology, including metaphors and similes, were used to describe fatigue reflecting its complex nature. Fatigue was presented as invisible, unpredictable, with constantly fluctuating daily patterns and severity. This made reporting fatigue difficult and at times lead to participants being challenged about its authenticity. The array of physical, psychological, cognitive and situational factors were perceived to contribute to fatigue, and different methods (e.g. sleep and rest, pacing, energy preservation, exercise, stress reduction, asking for help) were attempted by participants to manage fatigue. Most methods were not used systematically, possibly resulting in their apparently limited effectiveness. Impact of fatigue was perceived as negative, with participants constantly comparing their life and themselves as they were before fatigue and how much they have lost. They felt that fatigue is in control of their life and each day they had to fight another battle to defeat fatigue. Participants felt imprisoned in their fatigued unreliable body leaving them frustrated, isolated and lacking self-confidence. They reported loss of self and self-identity, resisting to accept the ‘new fatigued me’. <h3>Conclusion</h3> Fatigue is a major and debilitating symptom for individuals diagnosed with IBD, reducing their quality of life. The complex, invisible and fluctuating nature of fatigue makes difficult for patients to describe it to others. Patients need to be informed that fatigue is part of IBD and they should be encouragement to report and to seek help from health professionals. <h3>References</h3> 1 Czuber-Dochan W, Ream E, Norton C. Review article: description and management of fatigue in inflammatory bowel disease. <i>APT</i> 2013;<b>37</b>:505–16. 2 Czuber-Dochan W, Dibley L, Terry H, Ream E, Norton C. The experience of fatigue in people with inflammatory bowel disease: an exploratory study. <i>JAN</i> 2013;<b>69</b>:1987–99. 3 Van Manen M. Researching lived experience. 1997. The Althouse Press, London. <h3>Disclosure of Interest</h3> None Declared
SP0027 Confounding - Friend or Foe? How To Handle?
Authors: L. Carmona
Journal: Annals of the Rheumatic Diseases (2016)

Confounding is a major issue in observational studies, and it is a bias that needs to be corrected, controlled or adjusted for whatever your research question is. In this lecture we will review the definition of confounding and ways to tackle it. We will discuss two specific biases related to confounding in drug studies: confounding by indication and channelling bias. In addition, we will explain how to handle confounding in the different phases of research: 1) design phase, with an overview, among other issues, of what causal diagrams (directed acyclic graphs, DAG) are; 2) data collection and mining; 3) and finally analysis and reporting. In this latter part, we will explain how confounding is explored in datasets and the difference between confounding and modification. We will end with an overview of propensity scores, as a ways to tackle confusion in an efficient way, and a list of recommendations. <h3>Disclosure of Interest</h3> None declared
Bi-Specific Killer Cell Engagers (BiKEs) Signaling Through CD16 and Targeting CD33 (CD16 × CD33), Triggers Natural Killer (NK) Cell Cytotoxic and Cytokine Production Against Refractory Acute Myeloid Leukemia (AML)
Authors: Andres Wiernik, Bree Foley, Bin Zhang, Michael R. Verneris, Erica Warlick, Julie A. Ross, Louis M. Weiner, Daniel J. Weisdorf, Daniel A Vallera, Jeffrey S. Miller
Journal: Blood (2012)